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EFFECTS OF ADDING CHEMOTHERAPY-SPECIFIC DISCONTINUATION 
AND DOSE DELAY/REDUCTIONS TO FEBRILE NEUTROPENIA 
PROPHYLAXIS DECISION MODELS
Ozer-Deniz S1, Taylor DC1, Hill GJ1, Skornicki ME1, Barron R2
1i3Innovus, Medford, MA, USA, 2AMGEN, Thousand Oaks, CA, USA
OBJECTIVES: Relative dose intensity (RDI) is generally deﬁned as a patient’s actual 
received chemotherapy dose over time period versus the intended dose over time where 
RDI <85% can be considered sub-optimal. Published cost-effectiveness analyses of 
febrile neutropenia (FN) prophylaxis modeled RDI assuming a ﬁxed percentage of 
patients achieve low RDI. The objective of this study was to model the reasons for 
low RDI explicitly and evaluate the effects on results. METHODS: A lifetime Markov 
model of FN prophylaxis in the treatment of stage II breast cancer using TAC (FN 
risk ≥20%) and AC-T (FN risk <20%) chemotherapy was developed. Three FN 
prophylaxis strategies were compared: primary prophylaxis with pegﬁlgrastim (PPP), 
or with 6-day ﬁlgrastim (6D-PPF), and no prophylaxis (NP). RDI is modeled under 
two different scenarios: “ﬁxed rate” where ﬁxed proportion of patients receives low 
RDI and “ﬂexible rate” where low RDI is function of chemotherapy-speciﬁc discon-
tinuation and dose delay/reduction due to FN or other adverse events. Total costs and 
quality adjusted life years (QALYS) are accumulated in the model and results are 
reported in terms of incremental cost-effectiveness ratios (ICERs). All model param-
eters are estimated from published literature or expert opinion. RESULTS: In the TAC 
ﬁxed rate scenario, results demonstrate that PPP dominates (less costly and more 
effective) both 6D-PPF and NP. In TAC ﬂexible scenario, PPP also dominates both 
6D-PPF and NP. In AC-T there is more variation in results; In the ﬁxed rate scenario, 
PPP weakly dominates 6D-PPF, and the ICER versus NP is $106,700 per QALY 
gained, in the AC-T ﬂexible scenario the ICER is $54,800 per QALY gained versus 
NP. CONCLUSIONS: Explicitly modeling discontinuations and dose delay/reductions 
can substantially affect model ICERS and subsequent willingess-to-pay interpretation, 
especially in lower-risk regimens. Furthermore, explicit modeling permits the ﬂexibility 
to examine the effects of each factor alone.
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COST COMPARISON OF INPATIENT AND OUTPATIENT HOSPITAL-
BASED SERVICES BETWEEN TWO STRATEGIES FOR TREATMENT OF 
CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN A 
PUBLICLY FUNDED HEALTH CARE SYSTEM
Furlong W1, Rae CS2, Weitzman S3, Barr RD2
1Health Utilities Inc., Dundas, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 
3The Hospital for Sick Children, Toronto, ON, Canada
OBJECTIVES: To assess incremental total cost between two internationally utilized 
treatment strategies for ALL during childhood: Berlin-Frankfurt-Munich (BFM); and 
Dana-Farber Cancer Institute (DFCI). METHODS: Eligible patients were diagnosed 
after April 1, 2002 and completed treatment by March 31, 2007 at Hospital for Sick 
Children (BFM) or McMaster Children’s Hospital (DFCI) in Canada. Total cost for 
each patient was the sum of inpatient and outpatient service costs. Inpatient cost was 
measured using resource intensity weights from the Canadian Institute of Health 
Information (CIHI) Discharge Abstract Database and standard average inpatient cost 
per weighted case in ﬁscal year. Outpatient cost was measured using encounter codes 
from the CIHI National Ambulatory Care Reporting System and the standard cost 
per encounter code from the Ontario Case Costing Initiative. The Ontario Health 
Insurance Plan Schedule of Physician Fees provided physician costs. Costs were 
adjusted for inﬂation, discounted at 5% per year, and reported in 2007 Canadian 
dollars. Statistical signiﬁcance, set at p < 0.05, was tested using chi-square and 
ANOVA. RESULTS: Costs were measured for 66 BFM (41 standard- and 25 high-
risk) and 28 DFCI (19 standard- and 9 high-risk) patients. There was no signiﬁcant 
difference between BFM and DFCI strategies in risk group proportions (p = 0.597). 
Mean total cost varied by risk group (p = 0.029) but not overall strategy (p = 0.866). 
The BFM minus DFCI difference of mean total cost was $-12,679 (p = 0.336) for 
standard-risk patients, $29,576 (p = 0.140) for high-risk patients, and $2,725 (p = 
0.777) for pooled risk patients. The mean total cost for pooled patients was $101,484 
(SD = $38,296) for BFM and $98,760 (SD = $51,171) for DFCI. CONCLUSIONS: 
The incremental cost between the BFM and DFCI strategies was small and insigniﬁ-
cant. Future analyses will focus on incremental treatment effectiveness of BFM and 
DFCI strategies: mean health-related quality of life utility scores during and after 
treatment; and quality-adjusted life years.
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RECENT ERYTHROPOIESIS STIMULATING AGENT (ESA) UTILIZATION 
AND COSTS IN MEDICARE PATIENTS WITH CANCER RECEIVING 
CHEMOTHERAPY (CRC)
Kokkotos FK1, Bailey RA2, Kerr M1, Shen S1, Senbetta M2, McKenzie RS2
1Trinity Partners, LLC, Waltham, MA, USA, 2Centocor Ortho Biotech Services, LLC, 
Horsham, PA, USA
OBJECTIVES: To evaluate recent epoetin alfa (EPO) and darbepoetin alfa (DARB) 
drug utilization in CRC Medicare patients treated in the hospital outpatient setting. 
METHODS: An analysis of longitudinal medical claims in CRC Medicare patients 
using the Medicare 100% Institutional Database was performed to evaluate EPO and 
DARB utilization from 2005 to 2007. Patients included had ≥1 non-myeloid cancer 
diagnosis, were ESA treatment naïve, received chemotherapy during the preceding or 
same quarter as ESA treatment, and received ≥2 doses of EPO or DARB. Patients 
diagnosed with chronic kidney disease, myelodysplastic syndrome, treated with both 
agents within the same quarter, or received dialysis were excluded. A treatment episode 
was deﬁned as the time from the quarter of the ﬁrst ESA dose to the quarter of the 
last ESA dose. Mean cumulative ESA dose was used to calculate drug costs using April 
2009 wholesale acquisition costs (EPO $14.44/1000 units; DARB $5.064/mcg). 
RESULTS: A total of 19,028 EPO and 29,130 DARB treated CRC patients were 
identiﬁed between 2Q2005 and 4Q2007. The age distribution, the proportion of 
females, and the proportion receiving IV iron were similar between the groups. The 
EPO group had a lower mean (SD) Charlson Comorbidity Score [5.1(3.2)EPO; 
5.5(3.2)DARB, P < 0.001]. Mean (SD) treatment duration was 1.9(1.1) quarters for 
EPO; 2.0(1.1) quarters for DARB (P value <0.001). Mean (SD) cumulative dose was 
356,800(357,700)units for EPO; 1,371(1230)mcg for DARB. The observed dose ratio 
(EPO units/DARB mcg) was 260:1. ESA drug costs per treatment episode were $5,153 
for EPO and $6,944 for DARB. Overall ESA drug costs were $1,791 higher (P < 
0.001) for DARB, representing a 35% higher cost compared to EPO. CONCLU-
SIONS: This study of Medicare CRC patients treated with ESA in the hospital out-
patient setting observed 35% higher ESA drug costs in patients treated with DARB 
compared to EPO.
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OPEN VERSUS LAPAROSCOPIC PROCEDURES FOR COLECTOMY 
SURGERY FOR PATIENTS WITH COLON RECTAL CANCER: AN 
ANALYSIS OF OPPORTUNITY COSTS, UNDER THE PERSPECTIVE OF  
A PRIVATE HOSPITAL IN BRAZIL
Nasciben V, Saggia MG
Johnson & Johnson, Sao Paulo-SP, Brazil
OBJECTIVES: To identify if there are opportunity costs of two different surgery 
techniques [open (OP) versus laparoscopic (LAP)] for colon rectal cancer surgery 
under the perspective of a private hospital in Brazil. METHODS: According to the 
literature (King, 2006), LAP allows reduction of 32% of the length-of-stay (LOS) for 
patients that underwent colectomy (9 days for OP vs. 6 days for LAP). A 7% conver-
sion during the intervention from LAP to OP was considered since this was also 
reported (King, 2006) and conﬁrmed by the opinion of specialists. An analytical deci-
sion model was built under a hospital standpoint. Only direct medical costs were 
considered. The base-case scenario assumed a full reimbursement scheme for devices 
(SIMPRO, 2009). For medical fees, ICU and in-patient costs, the CBHPM 5th edition 
(Brazilian fee list) and the PROAHSA report were taken. Different LOS scenarios were 
simulated ranging from 8 days until 22 according to the literature review. A discount 
rate was not considered because the time horizon was shorter than one year. 
RESULTS: For patients that underwent OP the adoption of LAP would save from 2.6 
days to 7 days. This reduction in LOS could generate cost opportunities ranging from 
R$80, for 2.6 days reduction to R$1270, for 7 days reduction. CONCLUSIONS: 
Findings suggest LAP allows a faster discharge of patients that underwent colon rectal 
surgery providing the hospital with the opportunity to reduce the LOS and, as a 
consequence, streamline both the use of both hospital facilities and other medical 
resources.
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ECONOMIC BURDEN OF MYELODYSPLASTIC SYNDROMES AMONG US 
MEDICARE BENEFICIARIES: INCREASED COSTS IN TRANSFUSION 
DEPENDENT PATIENTS
Goldberg SL1, Chen E2, Corral M3, Guo A4, Laouri M5
1John Theurer Cancer Center, Hackensack, NJ, USA, 2Quorum Consulting, San Francisco, 
CA, USA, 3Novartis Oncology, East Hanover, NJ, USA, 4Novartis Pharmaceuticals 
Corporation, East Hanover, NJ, USA, 5Quorum Consulting Inc, San Francisco, CA, USA
OBJECTIVES: Previous studies have shown that patients with myelodysplastic syn-
dromes (MDS) requiring blood transfusions are at increased risk of developing co-
morbidities. This study sought to determine the Medicare costs in the ﬁrst 3 years 
following MDS diagnosis and evaluate whether blood transfusion dependent MDS 
patients incur additional costs. METHODS: A retrospective review of Medicare Stan-
dard Analytic Files was performed. Patients with ICD-9-CM code 238.7 in the ﬁrst 
quarter of 2003, with no prior diagnosis of anemias of known causes or myeloid 
leukemia, were identiﬁed and followed until death or end of 2006. Health care 
resource use and total Medicare costs of MDS patients who received blood transfusion 
vs those who did not during the study period were compared. This timeframe predates 
the widespread use of “low intensity chemotherapy agents”. RESULTS: 512 patients 
aged ≥65 years were diagnosed with MDS in the ﬁrst quarter of 2003. 205 (40%) of 
these patients received blood transfusion during the study period. No signiﬁcant dif-
ferences were observed with respect to age, gender and race among transfused and 
non-transfused patients. Patients requiring transfusions had an increased prevalence 
of cardiac diseases, diabetes, dyspnea, hepatic disease and infections. During the 3-year 
follow-up, a higher percentage of transfused patients was hospitalized (91.2% vs. 
67.1%, P < 0.001), admitted to emergency room (87.8% vs. 73.9%, P < 0.001), 
received growth factor treatments (59.5% vs. 26.4%, P < 0.001) and developed 
hemachromatosis (3.4% vs. 1.6%, P = 0.191) than non-transfused patients. Three-
year total Medicare costs were $88, 824 per transfused patient and $29,519 per 
non-transfused patient (p < 0.001). Hospital inpatient care and physician care consti-
tuted 43% and 31% of the total costs, respectively. CONCLUSIONS: MDS patients 
receiving transfusion were associated with end-organ impairment and incurred signiﬁ-
cantly higher Medicare costs than patients not receiving transfusions.
